PubMed:32118639 JSONTXT 18 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-97 DRI_Background denotes Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients.
T2 98-227 DRI_Background denotes BACKGROUND: A patient's infectivity is determined by the presence of the virus in different body fluids, secretions, and excreta.
T3 228-370 DRI_Background denotes The persistence and clearance of viral RNA from different specimens of patients with 2019 novel coronavirus disease (COVID-19) remain unclear.
T4 371-609 DRI_Background denotes This study analyzed the clearance time and factors influencing 2019 novel coronavirus (2019-nCoV) RNA in different samples from patients with COVID-19, providing further evidence to improve the management of patients during convalescence.
T5 610-799 DRI_Background denotes METHODS: The clinical data and laboratory test results of convalescent patients with COVID-19 who were admitted to from January 20, 2020 to February 10, 2020 were collected retrospectively.
T6 800-963 DRI_Background denotes The reverse transcription polymerase chain reaction (RT-PCR) results for patients' oropharyngeal swab, stool, urine, and serum samples were collected and analyzed.
T7 964-1174 DRI_Background denotes Convalescent patients refer to recovered non-febrile patients without respiratory symptoms who had two successive (minimum 24 h sampling interval) negative RT-PCR results for viral RNA from oropharyngeal swabs.
T8 1175-1341 DRI_Outcome denotes The effects of cluster of differentiation 4 (CD4)+ T lymphocytes, inflammatory indicators, and glucocorticoid treatment on viral nucleic acid clearance were analyzed.
T9 1449-1553 DRI_Background denotes In total, 28 (42.4%) women and 38 men (57.6%) with a median age of 44.0 (34.0-62.0) years were analyzed.
T10 1554-1660 DRI_Background denotes After in-hospital treatment, patients' inflammatory indicators decreased with improved clinical condition.
T11 1661-1810 DRI_Outcome denotes The median time from the onset of symptoms to first negative RT-PCR results for oropharyngeal swabs in convalescent patients was 9.5 (6.0-11.0) days.
T12 1811-2066 DRI_Outcome denotes By February 10, 2020, 11 convalescent patients (16.7%) still tested positive for viral RNA from stool specimens and the other 55 patients' stool specimens were negative for 2019-nCoV following a median duration of 11.0 (9.0-16.0) days after symptom onset.
T13 2067-2232 DRI_Outcome denotes Among these 55 patients, 43 had a longer duration until stool specimens were negative for viral RNA than for throat swabs, with a median delay of 2.0 (1.0-4.0) days.
T14 2233-2426 DRI_Outcome denotes Results for only four (6.9%) urine samples were positive for viral nucleic acid out of 58 cases; viral RNA was still present in three patients' urine specimens after throat swabs were negative.
T15 2427-2666 DRI_Approach denotes Using a multiple linear regression model (F = 2.669, P = 0.044, and adjusted R = 0.122), the analysis showed that the CD4+ T lymphocyte count may help predict the duration of viral RNA detection in patients' stools (t = -2.699, P = 0.010).
T16 2667-3122 DRI_Approach denotes The duration of viral RNA detection from oropharyngeal swabs and fecal samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (15 days vs. 8.0 days, respectively; t = 2.550, P = 0.013) and the duration of viral RNA detection in fecal samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (20 days vs. 11 days, respectively; t = 4.631, P < 0.001).
T17 3123-3303 DRI_Outcome denotes There was no statistically significant difference in inflammatory indicators between patients with positive fecal viral RNA test results and those with negative results (P > 0.05).
T18 3304-3498 DRI_Outcome denotes CONCLUSIONS: In brief, as the clearance of viral RNA in patients' stools was delayed compared to that in oropharyngeal swabs, it is important to identify viral RNA in feces during convalescence.
T19 3499-3678 DRI_Background denotes Because of the delayed clearance of viral RNA in the glucocorticoid treatment group, glucocorticoids are not recommended in the treatment of COVID-19, especially for mild disease.
T20 3679-3742 DRI_Approach denotes The duration of RNA detection may relate to host cell immunity.